Multiplexed Point-of-Care Testing – xPOCT. Issue 8 (August 2017)

• Record Type: Journal Article
• Authors: Dincer, Can; Bruch, Richard; Kling, André; Dittrich, Petra S.; Urban, Gerald A.
• Is Part Of: Trends in biotechnology. Volume 35:Issue 8(2017)
• Page Start: 728
• Page End: 742
• Publication Date: 2017-08
• Subjects: lab-on-a-chip (LOC) -- microfluidics -- multianalyte analysis -- multiplexing -- on-site testing -- point-of-care testing (POCT); Biotechnology -- Periodicals; Biochemical engineering -- Periodicals; Genetic engineering -- Periodicals; Industrial microbiology -- Periodicals; 660.605
• DOI: 10.1016/j.tibtech.2017.03.013
• Languages: English
• ISSNs: 0167-7799

Abstract

Abstract : Multiplexed point-of-care testing (xPOCT), which is simultaneous on-site detection of different analytes from a single specimen, has recently gained increasing importance for clinical diagnostics, with emerging applications in resource-limited settings (such as in the developing world, in doctors' offices, or directly at home). Nevertheless, only single-analyte approaches are typically considered as the major paradigm in many reviews of point-of-care testing. Here, we comprehensively review the present diagnostic systems and techniques for xPOCT applications. Different multiplexing technologies (e.g., bead- or array-based systems) are considered along with their detection methods (e.g., electrochemical or optical). We also address the unmet needs and challenges of xPOCT. Finally, we critically summarize the in-field applicability and the future perspectives of the presented approaches. Trends: Simultaneous on-site measurement of different substances from a single sample, called multiplexed point-of-care testing, has recently become more and more important for in vitro diagnostics. The major aim for the development of xPOCT systems is the smart combination of a high-performing device with a low system complexity. Thus, the on-site tests are realized in a short time by non-experts and ensure comparable results with clinical and central laboratory findings. A multiplexing capability of up to 10 analytes has been sufficient for many recent xPOCT applications. The future of xPOCT devices will be driven by novel biotechnologies (e.g., aptamers) or targets (e.g., circulating RNAs or tumor cells, exosomes, and miRNAs), as well as applications like personalized medicine, homecare monitoring, and wearables.